Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05152966
Other study ID # CS1335
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 16, 2021
Est. completion date December 1, 2022

Study information

Verified date February 2024
Source Farapulse, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this safety and feasibility study is to assess whether the endocardial creation of electrically nonconductive lesions via PEF catheter ablation applied using the FARAPULSE Cardiac Ablation System Plus is a feasible and safe treatment for PersAF and associated AFL


Description:

This is a prospective, multi-center safety and feasibility study in subjects with persistent AF. Subjects will undergo percutaneous PEF ablation for pulmonary vein isolation as well as cavotricuspid isthmus interruption and other left atrial ablations at the investigator's discretion. Subjects will then be followed at 30 days, 60 ± 15 days, 6 months and 12 months for adverse events, recurrence of arrhythmia after a 90 day blanking period and other relevant outcome measures.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 1, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Key Inclusion Criteria: Patients are required to meet all the following inclusion criteria to participate in this study: - Age 18-75 Patients with documented drug-resistant symptomatic persistent AF 1. Patient is refractory or intolerant to at least one Class I/III antiarrhythmic agent. 2. ECG-documented first episode of persistent AF, lasting longer than 7 days but not longer than 365 days 3. Holter within 90 days prior to the Enrollment Date demonstrating 24 hours of continuous AF 3. Patient participation requirements: 1. Lives locally 2. Is willing and capable of providing Informed Consent to undergo study procedures 3. Is willing to participate in all examinations and follow-up visits and tests associated with this clinical study. Exclusion Criteria: Subjects will be excluded from participating in this study if they meet any one of the following exclusion criteria: 1. AF that is: 1. Paroxysmal (longest AF episode < 7days) 2. Longstanding (has persisted > 12 months or that does not respond to cardioversion if < 12 months) 3. Secondary to electrolyte imbalance, thyroid disease, alcohol abuse or other reversible / non-cardiac causes 2. Left atrial anteroposterior diameter = 5.5 cm as documented by transthoracic echocardiography (TTE) or computed tomography (CT) 3. Any of the following cardiac procedures, implants or conditions: 1. Clinically significant arrhythmias other than AF, AFL or AT 2. Hemodynamically significant valvular disease 3. Prosthetic heart valve 4. NYHA Class III or IV CHF 5. Previous endocardial or epicardial ablation or surgery for AF 6. Atrial or ventricular septal defect closure 7. Atrial myxoma 8. Left atrial appendage device or occlusion 9. Pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices 10. Significant or symptomatic hypotension 11. Bradycardia or chronotropic incompetence 12. History of pericarditis 13. History of rheumatic fever 14. History of congenital heart disease with any residual anatomic or conduction abnormality 4. Any of the following within 3 months prior toenrollment: 1. Myocardial infarction 2. Unstable angina 3. Percutaneous coronary intervention 4. Heart surgery (e.g. coronary artery bypass grafting, ventriculotomy, atriotomy) 5. Heart failure hospitalization 6. Stroke or TIA 7. Clinically significant bleeding 8. Pericarditis or pericardial effusion 9. Left atrial thrombus 5. History of blood clotting or bleeding abnormalities. 6. Contraindication to, or unwillingness to use, systemic anticoagulation 7. Contraindications to CT or MRI 8. Sensitivity to contrast media not controlled by premedication 9. Women of childbearing potential who are pregnant, lactating or not using birth control 10. Medical conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or confound data or its interpretation, including but not limited to 1. Body mass index (BMI) > 40 2. Solid organ or hematologic transplant, or currently being evaluated for an organ transplant 3. Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea 4. Renal insufficiency with an estimated creatinine clearance <30 mL/min/1.73 m2, or any history of renal dialysis or renal transplant 5. Active malignancy or history of treated cancer within 24 months of enrollment 6. Clinically significant gastrointestinal problems involving the esophagus, stomach and/or untreated acid reflux 7. Clinically significant infection 8. Predicted life expectancy less than one year 11. Clinically significant psychological condition that in the investigator's opinion would prohibit the subject's ability to meet the protocol requirements 12. Current or anticipated enrollment in any other clinical study 13. Employment by FARAPULSE or the same hospital department or office of any investigator, or a family member of any of the preceding groups. 14. Use of amiodarone after day of index ablation procedure. Patients will cease use of amiodarone on or before the date of the index ablation procedure.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Ablation
Ablation using the FARAPULSE™ Cardiac Ablation System Plus

Locations

Country Name City State
Czechia Nemocnice Na Homolce Prague

Sponsors (1)

Lead Sponsor Collaborator
Farapulse, Inc.

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite Safety Endpoint;Proportion of Intent to Treat Subjects With One or More of the Specified Device or Procedure Related SAEs Proportion of Intent to Treat subjects with one or more of the specified device or procedure related SAEsEndpoint(CSE) defined as the incidence of the following early-onset serious adverse events (SAEs) which are device- or procedure-related, as adjudicated by the Clinical Events and Data Monitoring Committee (CEDMC). Atrioesophageal fistula and PV stenosis components will be assessed for occurrence at any time during follow-up. 7 days
Primary Composite Safety Endpoint;Proportion of Intent to Treat Subjects With One or More of the Specified Device or Procedure Related SAEs Proportion of Intent to Treat subjects with one or more of the specified device or procedure related SAEsEndpoint(CSE) defined as the incidence of the following late-onset serious adverse events (SAEs) which are device- or procedure-related, as adjudicated by the Clinical Events and Data Monitoring Committee (CEDMC). 12 Months
Primary Acute Procedural Success; Acute Vein Succes Demonstration of Acute Vein Success in all attempted PVs using the FARAPULSE Cardiac Ablation System Plus during the first ablation procedure (Index or Rescheduled Index Procedure) Index Procedure
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT03650556 - Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation N/A
Recruiting NCT04085731 - Driver-guided Ablation of Persistent Atrial Fibrillatiom
Withdrawn NCT02344394 - Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation N/A
Terminated NCT01683045 - Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats N/A
Completed NCT01694563 - ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation N/A
Active, not recruiting NCT03643224 - DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation N/A
Withdrawn NCT05093868 - Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF) N/A
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Active, not recruiting NCT06124690 - Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas N/A
Not yet recruiting NCT05454111 - CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation N/A
Completed NCT06260670 - FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation N/A
Active, not recruiting NCT05077670 - Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm
Withdrawn NCT03835338 - WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm N/A
Completed NCT02275104 - Multimodal Image Processing Software to Guide Cardiac Ablation Therapy N/A
Not yet recruiting NCT05565183 - Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation. N/A
Completed NCT02274857 - Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures N/A
Completed NCT01014741 - Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation N/A